

**Diaceutics PLC**  
**("Diaceutics" or the "Company")**

**Directorate change**

Diaceutics PLC (AIM: DXRX), announces the appointment of Deborah Davis as Non-Executive Chair, effective from 4 January 2021. Deborah has extensive global experience in platform business models, software, fintech, telecoms and e-commerce businesses.

After completing her undergraduate studies in Australia, Deborah spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay, and technology companies Symantec and Verizon.

She currently holds a number of Non-Executive Director and Board committee positions, including International Personal Finance plc, IDEX Biometrics ASA, Norway, The Institute of Directors UK and Which? Ltd (until 31/12/20). Her previous Board experience also includes private equity based ieDigital. Deborah is a trustee of the Southern African Conservation Trust.

Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Masters in Science (Management) with Distinction from London Business School.

**Peter Keeling, Chief Executive Officer of Diaceutics said:** *"I am delighted to attract someone of Deborah's relevant technology background and global experience to join our mission at Diaceutics. With the recent pivotal launch of our DXRX - Precision Testing Network platform, we have truly entered a new chapter in the Company's trajectory and I look forward to working with Deborah to capitalise on this."*

**Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:**

Deborah Lee Davis (Llewelyn), aged 57, is currently or has previously been a director or partner of the following directorships or partnerships within the past five years:

<i>Current directorships/partnerships</i>	<i>Historic directorships/partnerships</i>
IPF PLC	IE DIGITAL (formerly Intelligent Environments Europe)
Institute of Directors	
IDEX Biometrics ASA	
WHICH? LTD	
SA CONSERVATION TRUST	

Save for the information disclosed above, there is no other information to be disclosed on Deborah Davis under Schedule 2(g) of the AIM Rules.

Deborah holds no shares in the Company.

**Enquiries:**

**Diaceutics PLC**  
Peter Keeling, Chief Executive Officer  
Philip White, Chief Financial Officer

[www.diaceutics.com](http://www.diaceutics.com)  
via Walbrook PR

**Cenkos Securities plc (Nominated adviser and broker)**  
Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

+44 (0) 20 7391 8900

**Walbrook PR**  
Anna Dunphy  
Paul McManus

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)  
Mob: +44 (0)7876 741 001  
Mob: +44 (0)7980 541 893

**About Diaceutics**

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially

useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. [www.diaaceutics.com](http://www.diaaceutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAKKDBNOBDDCBB